NIPT
Researchers confirmed prior data showing 100 percent accuracy for the test, but in a clinical-use population where they also observed growing adoption by physicians.
Federal Judge Overturns $96M Jury Verdict in Natera, CareDx Patent Case
A US District Court judge found Natera's claims of patent infringement invalid, while denying CareDx's motion for a new trial.
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.
Investigators Urge Additional Screening to Catch Maternal Cancer From Nonreportable NIPT Results
An NIH team detected maternal cancers in nearly half of individuals with unusual or nonreportable findings from cell-free DNA-based fetal aneuploidy tests.
Dec 22, 2023
Wells Fargo Initiates Coverage of Revvity
Jul 31, 2023
Juno Diagnostics Ceases Commercial Operations
Apr 27, 2023
Apr 19, 2023
Ravgen Prevails Over Streck in Patent Challenge
Apr 17, 2023
Illumina, Ravgen Settle Patent Lawsuit Over NIPTs
Jan 25, 2023